Viekira Xr is a drug owned by Abbvie Inc. It is protected by 22 US drug patents filed from 2016 to 2019. Out of these, 20 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 02, 2035. Details of Viekira Xr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | |||
| US8501238 | Anti-infective agents and uses thereof |
Sep, 2028
(4 years from now) | Active |
| US8188104 | Anti-infective agents and uses thereof |
May, 2029
(4 years from now) | Active |
| US8642538 | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | Active |
| US8420596 | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(6 years from now) | Active |
| US8691938 | Anti-viral compounds |
Apr, 2032
(7 years from now) | Active |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7148359 | Polymorph of a pharmaceutical |
Jul, 2019
(5 years ago) |
Expired
|
| US7364752 | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) |
Expired
|
| US8268349 | Solid pharmaceutical dosage form |
Aug, 2024
(28 days from now) | Active |
| US8399015 | Solid pharmaceutical dosage form |
Aug, 2024
(28 days from now) | Active |
| US9139536 | Anti-infective agents and uses thereof |
Nov, 2028
(4 years from now) | Active |
| US9006387 | Anti-viral compounds |
Jun, 2030
(5 years from now) | Active |
| US9044480 | Compositions and methods for treating HCV |
Apr, 2031
(6 years from now) | Active |
| US8686026 | Solid compositions |
Jun, 2031
(6 years from now) | Active |
| US10201584 | Compositions and methods for treating HCV |
May, 2032
(7 years from now) | Active |
| US10201541 | Compositions and methods for treating HCV |
May, 2032
(7 years from now) | Active |
| US8680106 | Methods for treating HCV |
Sep, 2032
(8 years from now) | Active |
| US8466159 | Methods for treating HCV |
Sep, 2032
(8 years from now) | Active |
| US8685984 | Methods for treating HCV |
Sep, 2032
(8 years from now) | Active |
| US8492386 | Methods for treating HCV |
Sep, 2032
(8 years from now) | Active |
| US9744170 | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | Active |
| US9333204 | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | Active |
| US10105365 | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Viekira Xr's patents.
Latest Legal Activities on Viekira Xr's Patents
Given below is the list of recent legal activities going on the following patents of Viekira Xr.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Oct, 2023 | US8188104 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Feb, 2023 | US9139536 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Nov, 2022 | US9044480 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Sep, 2022 | US9006387 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Jul, 2022 | US10201541 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Jul, 2022 | US10201584 |
| Post Issue Communication - Certificate of Correction | 10 May, 2022 | US9744170 |
| Email Notification | 04 May, 2022 | US9744170 |
| Electronic Review | 04 May, 2022 | US9744170 |
| Mail Certificate of Correction Memo | 03 May, 2022 | US9744170 |
FDA has granted several exclusivities to Viekira Xr. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Viekira Xr, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Viekira Xr.
Exclusivity Information
Viekira Xr holds 1 exclusivities. All of its exclusivities have expired in 2019. Details of Viekira Xr's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Several oppositions have been filed on Viekira Xr's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Viekira Xr's generic, the next section provides detailed information on ongoing and past EP oppositions related to Viekira Xr patents.
Viekira Xr's oppositions filed in EPO
Viekira Xr has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 15, 2016, by Ter Meer Steinmeister & Partner Patentanwälte Mbb. This opposition was filed on patent number EP11727080A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15176068A | Apr, 2019 | Aechter, Bernd | Revoked |
| EP11727080A | Apr, 2016 | KELTIE LLP | Patent maintained as amended |
| EP11727080A | Apr, 2016 | Ter Meer Steinmeister & Partner Patentanwälte mbB | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but Viekira Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Viekira Xr's family patents as well as insights into ongoing legal events on those patents.
Viekira Xr's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Viekira Xr's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 02, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Viekira Xr Generics:
There are no approved generic versions for Viekira Xr as of now.
About Viekira Xr
Viekira Xr is a drug owned by Abbvie Inc. It is used for treating HCV infection. Viekira Xr uses Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir as an active ingredient. Viekira Xr was launched by Abbvie in 2016.
Market Authorisation Date:
Viekira Xr was approved by FDA for market use on 22 July, 2016.
NCE-1 date:
NCE-1 date is also known as the four year date as it is four years after the original drug approval. Since the approval date for Viekira Xr is 22 July, 2016, its NCE-1 date is estimated to be 19 December, 2018
Active Ingredient:
Viekira Xr uses Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir as the active ingredient. Check out other Drugs and Companies using Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir ingredient
Treatment:
Viekira Xr is used for treating HCV infection.
Dosage:
Viekira Xr is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE | Discontinued | ORAL |